SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a significant surge in momentum driven by a combination of index rebalancing, active share buybacks, and high short interest that has led the community to draw parallels to previous parabolic short squeeze setups. Traders are closely monitoring a tight, institutional-heavy float as they anticipate that sustained upside could force short sellers to cover, potentially accelerating price movement toward key resistance levels.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors react to the company's annual shareholder meeting and news regarding a potential acquisition of eBay, sparking intense debate over whether these developments signal a strategic pivot or further dilution. The community remains deeply divided, with bulls highlighting long-term turnaround efforts while bears and frustrated retail holders point to stagnant price action and past failed squeeze predictions.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is currently in the spotlight following the FDA accelerated approval of Trutakna for primary IgA Nephropathy, a major clinical milestone that validates its commercial trajectory in the kidney disease space. While the stock has seen muted price action, the community is actively debating the significance of the broad label and potential for future commercial uptake against existing competitors.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is currently capturing investor attention following the FDA's decision to grant fast track designation to its lead chronic Hepatitis B candidate, imdusiran. The community is actively debating the stock's long-term valuation in light of this clinical progress, alongside ongoing patent litigation catalysts against major pharmaceutical firms and potential strategic takeover interest.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant investor attention as recent Phase 3 data and potential FDA approval milestones for its lead psychedelic program, COMP360, strengthen the company's commercial outlook for treatment-resistant depression. Community discussion is heavily focused on the stock's role as a first-mover in a nascent sector, with many participants tracking institutional interest, the upcoming NDA submission, and the potential for a transformative impact on psychiatric medicine.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trending as investors debate the stock's role as a critical AI infrastructure and data-layer provider versus broader concerns regarding international security policies and market valuations. The community is actively discussing the stock's potential for institutional re-rating, its strategic partnerships with firms like Nvidia, and the long-term outlook for enterprise AI adoption.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors digest a positive earnings report that highlights rapid revenue growth and a raised full-year outlook, fueling community speculation about a potential buyout. While supporters emphasize the long-term potential of the Recorlev franchise and the upcoming Phase 3 trial for the subcutaneous levothyroxine candidate XP-8121, others remain cautious, citing frustrations with management's communication and recurring delays in pipeline milestones.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under pressure as reports of Chinese AI startup DeepSeek developing custom chips to reduce reliance on foreign hardware trigger sector-wide anxiety about the sustainability of the AI infrastructure buildout. Despite these competitive headwinds, the community remains divided, with bulls viewing the dip as a value-buying opportunity based on strong fundamental demand, while bears point to persistent volatility and rotational shifts as signals of a cooling AI cycle.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to strong upward momentum driven by sector rotation into biotech and intense investor anticipation surrounding key clinical catalysts, including upcoming maintenance trial results. The community is actively debating the potential for a strategic partnership or buyout, as shareholders closely watch the company's progress in the competitive GLP-1 weight-loss market.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending as institutional interest surges following a $14 price target initiation by Mizuho and confirmed Breakthrough Therapy Designation for NXC-201. The community is actively discussing the potential for a strategic buyout or accelerated BLA timeline, with many investors focusing on the company's differentiated ex vivo CAR-T platform as a major differentiator in the AL amyloidosis space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sinclair (SBGI) Soars 6.7%: Is Further Upside Left in the Stock?

Sinclair (SBGI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sinclair (NASDAQ:SBGI) Given New $19.00 Price Target at Guggenheim

Guggenheim lowered their price objective on Sinclair from $20.00 to $19.00 and set a 'buy' rating for the company in a research note on Tuesday...

Capital Management Corp VA Has $21.24 Million Stock Holdings in Sinclair, Inc. $SBGI

Capital Management Corp VA cut its stake in shares of Sinclair, Inc. (NASDAQ:SBGI - Free Report) by 16.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,388,132 shares of the company's stock after se...

Wells Fargo & Company Lowers Sinclair (NASDAQ:SBGI) Price Target to $16.00

Wells Fargo & Company reduced their target price on shares of Sinclair from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday...

Sinclair, Inc. (NASDAQ:SBGI) Plans $0.25 Quarterly Dividend

Sinclair, Inc. (NASDAQ:SBGI) announced a quarterly dividend on Thursday, April 30th. Stockholders of record on Tuesday, May 26th will be paid a dividend of 0.25 per share on Tuesday, June 9th. This...

Sinclair Q1 Earnings Call Highlights

Sinclair (NASDAQ:SBGI) reported first-quarter 2026 results that executives said demonstrated the consistency of the broadcast business and the growth potential of Tennis Channel, as the company...

Sinclair (NASDAQ:SBGI) Announces Earnings Results

Sinclair (NASDAQ:SBGI - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $999.00 EPS for the quarter, topping analysts' consensus estimates of ($1.04) by...

Sinclair (SBGI) Beats Q1 Earnings and Revenue Estimates

Sinclair (SBGI) delivered earnings and revenue surprises of +141.48% and +1.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sinclair, Inc. (NASDAQ:SBGI) Given Consensus Recommendation of "Hold" by Brokerages

Sinclair, Inc. (NASDAQ:SBGI - Get Free Report) has been assigned a consensus rating of "Hold" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Two research...

Sinclair (SBGI) to Release Quarterly Earnings on Thursday

Sinclair (NASDAQ:SBGI) will be releasing its Q1 2026 earnings after the market closes on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-sinclair-broadcast-group-inc-stock...

Sinclair, Inc. is a media company that engages in providing content on local television stations and digital platforms. It also owns digital media products that are complementary to their extensive portfolio. It operates through the Local Media and Tennis segments. The company was founded by Julian Sinclair Smith in 1971 and is headquartered in Hunt Valley, MD.

Sinclair Inc - Ordinary Shares - Class A

EW Scripps Stock Sees Volatile Trading Session On Monday – What’s The Sinclair Angle?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.97
Prev Close	$15.14
Open	$15.38
Dividend Yield	6.54%
50-Day Moving Average	$14.27
Beta	1.07
Avg. Volume	537,374.13
PE Ratio	16.75

52-Week High	$17.88
52-Week Low	$11.89
Market Capitalization	$1.09B
EPS (Annual)	-$1.62
Price to Book	2.33
Revenue Per Employee	$446,338.03

Feed

News

Sentiment

Earnings

Fundamentals

Info

SBGISinclair Broadcast Group, Inc. - Ordinary Shares - Class A

Latest SBGI News